Healthy
Conditions
Keywords
Obesity, Overweight, Contrave, Antiobesity agents, Antiobesity drugs, Weight loss drug, Bioequivalence, Pharmacokinetic
Brief summary
This is a Phase 1, open-label, randomized, single-dose, 2-way crossover study in healthy adult subjects to assess the bioequivalence of naltrexone SR/bupropion SR combination trilayer tablets prepared at two different manufacturing sites. The pharmacokinetics of the two drug products will be evaluated separately in the fed and fasted state.
Interventions
DRUGReference naltrexone 8 mg SR/bupropion 90 mg SR combination trilayer tablets (2 tablets)
DRUGTest naltrexone 8 mg SR/bupropion 90 mg SR combination trilayer tablets (2 tablets)
Sponsors
Orexigen Therapeutics, Inc
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
Yes
Inclusion criteria
1. Male or female, 18 to 60 years of age, inclusive 2. Be in good general health, without any clinically significant medical history, physical examination findings, or laboratory results at Screening or Day -1 3. Body mass index (BMI) of 18 to 30 kg/m2, inclusive, at Screening
Exclusion criteria
1. Acute (within 28 days of Day -1) or chronic illness 2. History (within the last 20 years) of seizures, cranial trauma, bulimia, anorexia nervosa, or other conditions that may predispose the subject to seizures; or previous medical treatment with anticonvulsants of any type 3. History of mania or current diagnosis of active psychosis 4. Acute depressive illness, including new onset of depression or acute exacerbation of symptoms 5. Use of any prescription medication within 14 days prior to Day -1, with the exception of hormonal contraceptive or hormonal replacement therapy (HRT) at a stable dose for at least 28 days prior to Day -1 6. Use of any over-the-counter medications, including dietary/nutritional and herbal supplements, within 24 hours prior to study drug intake on Day 1 7. Use of bupropion- or naltrexone-containing products within 28 days prior to Day -1, or history of hypersensitivity or intolerance to naltrexone or bupropion 8. Have donated blood or have had significant blood loss within 90 days prior to Day -1; or have donated plasma within 7 days prior to Day -1 9. Hemoglobin concentration \<11 g/dL at Screening 10. Blood pressure \>140/90 mm Hg at Screening or Day -1 11. Women who are pregnant or trying to become pregnant, have a positive pregnancy test at Screening or Day -1, are currently breast-feeding, or are of childbearing potential (including perimenopausal women who have had a menstrual period within 1 year prior to Day -1) and are not willing to practice effective birth control. Women who are surgically sterile (including bilateral tubal ligation, tubal occlusion, hysterectomy or oophorectomy) are not considered to be of childbearing potential. 12. Drug or alcohol abuse or dependence within 6 months prior to Screening, or positive urine drug screen at Screening or Day -1 13. Regular daily use of tobacco products, including inhaled tobacco (e.g., cigarettes, cigars, pipes), chewing tobacco or snuff, or nicotine replacement products (including electronic cigarettes or nicotine vaporizers) within 28 days prior to Day -1 14. Unwilling to refrain from consumption of any citrus products (e.g., whole fruit, juice or products containing orange, grapefruit, or pomelo), alcohol or caffeine/xanthine-containing foods or beverages for 48 hours before study drug intake in each treatment period (Days 1 and 15) until 72 hours postdose (Days 4 and 18) 15. Inability or unwillingness to consume a standardized high-fat breakfast as provided at the study clinic on Days 1 and 15 16. Inability to comply with all required study procedures and schedule, inability to speak and read English, or unwillingness or inability to give written informed consent 17. Employee or immediate family member of the sponsor (or designee) or study site research staff 18. Use of any investigational drug, device, or procedure within 30 days prior to Day -1
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Cmax | 0-96 hours post-dose | Maximum observed plasma concentration |
| AUC(0-t) | 0-96 hours post-dose | Area under the plasma concentration-time curve from 0 hour to the time of the last quantifiable concentration |
| AUC(0-inf) | 0-96 hours post-dose | Area under the plasma concentration-time curve from 0 hour extrapolated to infinity |
Countries
United States
Outcome results
None listed